ZIOPHARM Oncology to Present at the 9th Annual JMP Securities Healthcare
BOSTON, June 18, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc.
(Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief
Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical
Development and Medical Operations will present at the 9th Annual JMP
Securities Healthcare Conference on Wednesday, June 25th, 2014 at 10:00 a.m.
ET at the Westin New York Grand Central in New York City.
To access a live audio webcast of the presentation, please visit the Investor
Relations section at www.ziopharm.com. The webcast will be archived for 90
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company
employing novel gene expression and control technology to deliver DNA for the
treatment of cancer. ZIOPHARM's technology platform employs Intrexon
Corporation's RheoSwitch Therapeutic System® technology to turn on and off,
and precisely modulate, gene expression at the cancer site in order to improve
the therapeutic index. This technology is currently being evaluated in Phase 2
clinical studies of the immune system cytokine interleukin-12 for the
treatment of breast cancer and advanced melanoma. Multiple new Investigational
New Drug Applications for new targets using synthetic biology technology are
expected through 2015. ZIOPHARM is also developing novel small molecules as
potential cancer therapeutics.
CONTACT: Lori Ann Occhiogrosso
Director of Corporate Communication
ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.